The Centers for Medicare & Medicaid Services denies coverage for a new class of Alzheimer’s drugs to all but a few beneficiaries who are enrolled in CMS-approved clinical studies or data registries. As a result, the majority of Medicare beneficiaries do not have access to these potentially life-changing medications.
In this webinar, leading pollsters Celinda Lake and Neil Newhouse, as well as subject matter experts Sue Peschin and George Vradenburg, share new public opinion data on Medicare’s controversial policy toward these medicines. Celinda, Neil, Sue, and George share insights from the survey on how the public, as well as Americans of different age groups, races, and political parties view Alzheimer’s disease and Medicare’s policy.
This webinar is an effort of the Alliance for Aging Research, UsAgainstAlzheimer’s, and the Partnership to Fight Chronic Disease.
source
